Raras
Buscar doenças, sintomas, genes...
Glioblastoma
ORPHA:360CID-10 · C71.9CID-11 · 2A00.00DOENÇA RARA

É o tipo mais agressivo de tumor cerebral que se forma a partir dos astrócitos (células de suporte do cérebro), classificado como Grau IV pela Organização Mundial da Saúde (OMS). Ele é formado por células tumorais (astrócitos) muito alteradas, que não se parecem com as células normais. Suas características incluem: células com formas e tamanhos variados, núcleos celulares anormais, muitas células se dividindo rapidamente, formação de coágulos nos vasos sanguíneos, aumento de pequenos vasos sanguíneos e áreas de tecido morto. Geralmente afeta adultos e se localiza principalmente nas maiores partes do cérebro, os hemisférios cerebrais. Ele pode se desenvolver a partir de outros tumores cerebrais menos agressivos, como o astrocitoma difuso Grau II ou o astrocitoma anaplásico. Nesses casos, é chamado de glioblastoma "secundário" e geralmente apresenta uma alteração genética específica (mutação IDH). No entanto, na maioria das vezes, ele aparece de repente, em pouco tempo, sem que houvesse um tumor menos grave antes. Nesses casos, é chamado de glioblastoma "primário" e não apresenta a mutação IDH.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

É o tipo mais agressivo de tumor cerebral que se forma a partir dos astrócitos (células de suporte do cérebro), classificado como Grau IV pela Organização Mundial da Saúde (OMS). Ele é formado por células tumorais (astrócitos) muito alteradas, que não se parecem com as células normais. Suas características incluem: células com formas e tamanhos variados, núcleos celulares anormais, muitas células se dividindo rapidamente, formação de coágulos nos vasos sanguíneos, aumento de pequenos vasos sanguíneos e áreas de tecido morto. Geralmente afeta adultos e se localiza principalmente nas maiores partes do cérebro, os hemisférios cerebrais. Ele pode se desenvolver a partir de outros tumores cerebrais menos agressivos, como o astrocitoma difuso Grau II ou o astrocitoma anaplásico. Nesses casos, é chamado de glioblastoma "secundário" e geralmente apresenta uma alteração genética específica (mutação IDH). No entanto, na maioria das vezes, ele aparece de repente, em pouco tempo, sem que houvesse um tumor menos grave antes. Nesses casos, é chamado de glioblastoma "primário" e não apresenta a mutação IDH.

Pesquisas ativas
32 ensaios
2197 total registrados no ClinicalTrials.gov
Publicações científicas
58.835 artigos
Último publicado: 2026 Apr 17

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
1.0
Worldwide
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: C71.9
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
3 sintomas
💪
Músculos
1 sintomas
👁️
Olhos
1 sintomas

+ 10 sintomas em outras categorias

Características mais comuns

100%prev.
Glioblastoma multiforme
90%prev.
Morfologia celular anormal
Muito frequente (99-80%)
55%prev.
Labilidade emocional
Frequente (79-30%)
55%prev.
Morfologia anormal da substância branca cerebral
Frequente (79-30%)
55%prev.
Fraqueza muscular
Frequente (79-30%)
55%prev.
Anormalidade da fisiologia do sistema nervoso
Frequente (79-30%)
15sintomas
Muito frequente (2)
Frequente (11)
Ocasional (2)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 15 características clínicas mais associadas, ordenadas por frequência.

Glioblastoma multiforme
Muito frequente100%
Morfologia celular anormalAbnormal cell morphology
Muito frequente (99-80%)90%
Labilidade emocionalEmotional lability
Frequente (79-30%)55%
Morfologia anormal da substância branca cerebralAbnormal cerebral white matter morphology
Frequente (79-30%)55%
Fraqueza muscularMuscle weakness
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico58.835PubMed
Últimos 10 anos200publicações
Pico2026200 papers
Linha do tempo
2026Hoje · 2026🧪 1979Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

13 genes identificados com associação a esta condição. Padrão de herança: Multigenic/multifactorial, Not applicable.

MGMTMethylated-DNA--protein-cysteine methyltransferaseCandidate gene tested inTolerante
FUNÇÃO

Involved in the cellular defense against the biological effects of O6-methylguanine (O6-MeG) and O4-methylthymine (O4-MeT) in DNA. Repairs the methylated nucleobase in DNA by stoichiometrically transferring the methyl group to a cysteine residue in the enzyme. This is a suicide reaction: the enzyme is irreversibly inactivated

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
MGMT-mediated DNA damage reversal
EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
38.0 TPM
Testículo
25.7 TPM
Tecido adiposo
25.1 TPM
Mama
24.2 TPM
Bladder
23.6 TPM
OUTRAS DOENÇAS (3)
gliosarcomafamilial melanomagiant cell glioblastoma
HGNC:7059UniProt:P16455
FGFR3Fibroblast growth factor receptor 3Candidate gene tested inAltamente restrito
FUNÇÃO

Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferat

LOCALIZAÇÃO

Cell membraneCytoplasmic vesicleEndoplasmic reticulumSecreted

VIAS BIOLÓGICAS (2)
Signaling by FGFR3 in diseaset(4;14) translocations of FGFR3
MECANISMO DE DOENÇA

Achondroplasia

A frequent form of short-limb dwarfism. It is characterized by a long, narrow trunk, short extremities, particularly in the proximal (rhizomelic) segments, a large head with frontal bossing, hypoplasia of the midface and a trident configuration of the hands. ACH is an autosomal dominant disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Not Sun Exposed Suprapubic
364.6 TPM
Skin Sun Exposed Lower leg
356.5 TPM
Esôfago - Mucosa
199.7 TPM
Brain Caudate basal ganglia
148.4 TPM
Brain Nucleus accumbens basal ganglia
135.4 TPM
OUTRAS DOENÇAS (19)
nevus, epidermalsevere achondroplasia-developmental delay-acanthosis nigricans syndromelacrimoauriculodentodigital syndrome 2testicular germ cell tumor
HGNC:3690UniProt:P22607
FGFR1Fibroblast growth factor receptor 1Candidate gene tested inAltamente restrito
FUNÇÃO

Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to the activati

LOCALIZAÇÃO

Cell membraneNucleusCytoplasm, cytosolCytoplasmic vesicle

VIAS BIOLÓGICAS (2)
Epithelial-Mesenchymal Transition (EMT) during gastrulationFormation of paraxial mesoderm
MECANISMO DE DOENÇA

Pfeiffer syndrome

A syndrome characterized by the association of craniosynostosis, broad and deviated thumbs and big toes, and partial syndactyly of the fingers and toes. Three subtypes are known: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
144.8 TPM
Ovário
142.9 TPM
Artéria tibial
134.1 TPM
Fallopian Tube
122.3 TPM
Cérebro - Hemisfério cerebelar
122.0 TPM
OUTRAS DOENÇAS (20)
Hartsfield-Bixler-Demyer syndromeencephalocraniocutaneous lipomatosisosteoglophonic dysplasiaPfeiffer syndrome
HGNC:3688UniProt:P11362
SEPTIN14Septin-14Candidate gene tested inTolerante
FUNÇÃO

Filament-forming cytoskeletal GTPase (Probable). Involved in the migration of cortical neurons and the formation of neuron leading processes during embryonic development (By similarity). Plays a role in sperm head formation during spermiogenesis, potentially via facilitating localization of ACTN4 to cell filaments (PubMed:33228246)

LOCALIZAÇÃO

CytoplasmCytoplasm, cytoskeletonCell projection, axonCell projection, dendritePerikaryonCytoplasm, perinuclear regionCytoplasmic vesicle, secretory vesicle, acrosome

OUTRAS DOENÇAS (2)
gliosarcomagiant cell glioblastoma
HGNC:33280UniProt:Q6ZU15
NFKBIANF-kappa-B inhibitor alphaCandidate gene tested inAltamente restrito
FUNÇÃO

Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL (RELA/p65 and NFKB1/p50) dimers in the cytoplasm by masking their nuclear localization signals (PubMed:1493333, PubMed:36651806, PubMed:7479976). On cellular stimulation by immune and pro-inflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription (PubMed:7479976, PubMed:7628694, PubMed:7796813, PubMed:7878466)

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (10)
RIP-mediated NFkB activation via ZBP1TRAF6 mediated NF-kB activationTAK1-dependent IKK and NF-kappa-B activation NF-kB is activated and signals survivalCLEC7A (Dectin-1) signaling
MECANISMO DE DOENÇA

Ectodermal dysplasia and immunodeficiency 2

A form of ectoderma dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. This form of ectodermal dysplasia is associated with decreased production of pro-inflammatory cytokines and certain interferons, rendering patients susceptible to infection. EDAID2 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
497.5 TPM
Nervo tibial
450.8 TPM
Baço
352.8 TPM
Ovário
332.9 TPM
Skin Not Sun Exposed Suprapubic
320.1 TPM
OUTRAS DOENÇAS (5)
ectodermal dysplasia and immunodeficiency 2ectodermal dysplasia and immune deficiencygiant cell glioblastomanasopharyngeal carcinoma
HGNC:7797UniProt:P25963
TACC3Transforming acidic coiled-coil-containing protein 3Candidate gene tested inTolerante
FUNÇÃO

Plays a role in the microtubule-dependent coupling of the nucleus and the centrosome. Involved in the processes that regulate centrosome-mediated interkinetic nuclear migration (INM) of neural progenitors (By similarity). Acts as a component of the TACC3/ch-TOG/clathrin complex proposed to contribute to stabilization of kinetochore fibers of the mitotic spindle by acting as inter-microtubule bridge. The TACC3/ch-TOG/clathrin complex is required for the maintenance of kinetochore fiber tension (P

LOCALIZAÇÃO

CytoplasmCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, spindleCytoplasm, cytoskeleton, spindle pole

VIAS BIOLÓGICAS (2)
Negative regulation of NOTCH4 signalingNOTCH3 Activation and Transmission of Signal to the Nucleus
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
122.0 TPM
Linfócitos
98.8 TPM
Sangue
80.8 TPM
Baço
44.0 TPM
Fibroblastos
29.4 TPM
OUTRAS DOENÇAS (2)
giant cell glioblastomagliosarcoma
HGNC:11524UniProt:Q9Y6A5
PPARGPeroxisome proliferator-activated receptor gammaCandidate gene tested inModerado
FUNÇÃO

Ligand-activated transcription factor that forms obligate heterodimers with the retinoic acid receptor and acts as a key regulator of biological processes, such as adipocyte differentiation, lipid metabolism, glucose homeostasis and beta-oxidation of fatty acids (PubMed:16150867, PubMed:20829347, PubMed:23525231, PubMed:8702406, PubMed:8706692, PubMed:9065481). Activated by lipid ligands: binds peroxisome proliferators, such as hypolipidemic drugs, and fatty acids, such as prostaglandin J2 metab

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (7)
Regulation of PTEN gene transcriptionTranscriptional regulation of white adipocyte differentiationPPARA activates gene expressionMECP2 regulates transcription factorsNuclear Receptor transcription pathway
EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
111.2 TPM
Adipose Visceral Omentum
100.8 TPM
Mama
71.3 TPM
Cólon transverso
21.6 TPM
Fibroblastos
20.4 TPM
OUTRAS DOENÇAS (6)
type 2 diabetes mellitusPPARG-related familial partial lipodystrophyinherited obesitygliosarcoma
HGNC:9236UniProt:P37231
EGFREpidermal growth factor receptorCandidate gene tested inRestrito
FUNÇÃO

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:10805725, PubMed:27153536, PubMed:2790960, PubMed:35538033). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:12297049, PubMed:15611079, PubMed:17909029, PubMed:20837704, PubMed:27153536, PubMed:2790960, PubMed:7679104, PubMed:8144591, PubM

LOCALIZAÇÃO

Cell membraneEndoplasmic reticulum membraneGolgi apparatus membraneNucleus membraneEndosomeEndosome membraneNucleusSecreted

VIAS BIOLÓGICAS (10)
Signaling by EGFRInhibition of Signaling by Overexpressed EGFRSignaling by ERBB2Signaling by ERBB4Signaling by ERBB2 TMD/JMD mutants
MECANISMO DE DOENÇA

Lung cancer

A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Sun Exposed Lower leg
78.3 TPM
Skin Not Sun Exposed Suprapubic
75.9 TPM
Fibroblastos
60.6 TPM
Nervo tibial
43.1 TPM
Vagina
40.6 TPM
OUTRAS DOENÇAS (4)
inflammatory skin and bowel disease, neonatal, 2lung cancergliosarcomagiant cell glioblastoma
HGNC:3236UniProt:P00533
TACC1Transforming acidic coiled-coil-containing protein 1Candidate gene tested inTolerante
FUNÇÃO

Involved in transcription regulation induced by nuclear receptors, including in T3 thyroid hormone and all-trans retinoic acid pathways (PubMed:20078863). Might promote the nuclear localization of the receptors (PubMed:20078863). Likely involved in the processes that promote cell division prior to the formation of differentiated tissues

LOCALIZAÇÃO

CytoplasmNucleusCytoplasm, cytoskeleton, microtubule organizing center, centrosomeMidbodyMembrane

VIAS BIOLÓGICAS (1)
Signaling by plasma membrane FGFR1 fusions
EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
142.9 TPM
Esôfago - Muscular
140.6 TPM
Útero
124.4 TPM
Esôfago - Junção
122.5 TPM
Tecido adiposo
119.2 TPM
OUTRAS DOENÇAS (2)
giant cell glioblastomagliosarcoma
HGNC:11522UniProt:O75410
TP53Cellular tumor antigen p53Candidate gene tested inAltamente restrito
FUNÇÃO

Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apop

LOCALIZAÇÃO

CytoplasmNucleusNucleus, PML bodyEndoplasmic reticulumMitochondrion matrixCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (10)
TP53 Regulates Metabolic GenesRegulation of TP53 ExpressionRegulation of TP53 DegradationOncogene Induced SenescenceOxidative Stress Induced Senescence
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
73.0 TPM
Skin Sun Exposed Lower leg
37.0 TPM
Skin Not Sun Exposed Suprapubic
35.2 TPM
Fibroblastos
32.9 TPM
Ovário
32.4 TPM
OUTRAS DOENÇAS (29)
Li-Fraumeni syndromenasopharyngeal carcinoma, susceptibility to, 1hepatocellular carcinomafamilial pancreatic carcinoma
HGNC:11998UniProt:P04637
IDH1Isocitrate dehydrogenase [NADP] cytoplasmicCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the NADP(+)-dependent oxidative decarboxylation of isocitrate (D-threo-isocitrate) to 2-ketoglutarate (2-oxoglutarate), which is required by other enzymes such as the phytanoyl-CoA dioxygenase (PubMed:10521434, PubMed:19935646). Plays a critical role in the generation of NADPH, an important cofactor in many biosynthesis pathways (PubMed:10521434). May act as a corneal epithelial crystallin and may be involved in maintaining corneal epithelial transparency (By similarity)

LOCALIZAÇÃO

Cytoplasm, cytosolPeroxisome

VIAS BIOLÓGICAS (3)
NADPH regenerationNFE2L2 regulating TCA cycle genesPeroxisomal protein import
MECANISMO DE DOENÇA

Glioma

Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
266.5 TPM
Fígado
100.4 TPM
Esôfago - Mucosa
99.8 TPM
Tecido adiposo
81.8 TPM
Próstata
77.7 TPM
OUTRAS DOENÇAS (7)
Maffucci syndromemetaphyseal chondromatosis with D-2-hydroxyglutaric aciduriaacute myeloid leukemia with multilineage dysplasiaOllier disease
HGNC:5382UniProt:O75874
ROS1Proto-oncogene tyrosine-protein kinase ROSCandidate gene tested inTolerante
FUNÇÃO

Receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. NELL2 is an endogenous ligand for ROS1. Upon endogenous stimulation by NELL2, ROS1 activates the intracellular signaling pathway and triggers epididymal epithelial differentiation and subsequent sperm maturation (By similarity). May activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including

LOCALIZAÇÃO

Cell membrane

EXPRESSÃO TECIDUAL(Tecido-específico)
Pulmão
11.1 TPM
Fibroblastos
3.0 TPM
Testículo
1.0 TPM
Córtex cerebral
0.8 TPM
Brain Frontal Cortex BA9
0.8 TPM
OUTRAS DOENÇAS (2)
cholangiocarcinomagiant cell glioblastoma
HGNC:10261UniProt:P08922
LZTR1Leucine-zipper-like transcriptional regulator 1Candidate gene tested inTolerante
FUNÇÃO

Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates ubiquitination of Ras (K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS) (PubMed:30442762, PubMed:30442766, PubMed:30481304). Is a negative regulator of RAS-MAPK signaling that acts by controlling Ras levels and decreasing Ras association with membranes (PubMed:30442762, PubMed:30442766, PubMed:30481304)

LOCALIZAÇÃO

Endomembrane systemRecycling endosomeGolgi apparatus

MECANISMO DE DOENÇA

Glioma

Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
76.5 TPM
Nervo tibial
68.8 TPM
Útero
67.8 TPM
Cervix Ectocervix
65.1 TPM
Cervix Endocervix
61.7 TPM
OUTRAS DOENÇAS (9)
Noonan syndrome 10RASopathyNoonan syndrome 2cafe au lait spots, multiple
HGNC:6742UniProt:Q8N653

Medicamentos aprovados (FDA)

3 medicamentos encontrados nos registros da FDA americana.

💊 TEMODAR (TEMOZOLOMIDE)
💊 Carmustine (CARMUSTINE)
💊 MVASI (BEVACIZUMAB-AWWB)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

1,746 variantes patogênicas registradas no ClinVar.

🧬 LZTR1: NM_006767.4(LZTR1):c.2085del (p.Met695fs) ()
🧬 LZTR1: NM_006767.4(LZTR1):c.549_563del (p.Tyr183_Trp188delinsTer) ()
🧬 LZTR1: NM_006767.4(LZTR1):c.2069+1G>T ()
🧬 LZTR1: GRCh38/hg38 22q11.21(chr22:18919477-21459713)x3 ()
🧬 LZTR1: GRCh38/hg38 22q11.21(chr22:19017218-21105423)x1 ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 18 variantes classificadas pelo ClinVar.

7
11
Patogênica (38.9%)
VUS (61.1%)
VARIANTES MAIS SIGNIFICATIVAS
PIK3R1: NM_181523.3(PIK3R1):c.1357_1362del (p.Asn453_Thr454del) [Likely pathogenic]
PTEN: NM_000314.8(PTEN):c.275A>T (p.Asp92Val) [Pathogenic]
LOC110806263: NM_198253.3(TERT):c.-124C>T [Conflicting classifications of pathogenicity]
SUZ12: NM_015355.4(SUZ12):c.1437+3_1437+6del [Uncertain significance]
FGFR2: t(10;19)(q26.13;q13.43) [Uncertain significance]

Vias biológicas (Reactome)

121 vias biológicas associadas aos genes desta condição.

MGMT-mediated DNA damage reversal PI3K Cascade PIP3 activates AKT signaling Signaling by activated point mutants of FGFR3 FGFR3b ligand binding and activation FGFR3c ligand binding and activation t(4;14) translocations of FGFR3 Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade; FGFR3 SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 Negative regulation of FGFR3 signaling Signaling by FGFR3 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR1 amplification mutants Signaling by activated point mutants of FGFR1 FGFR1b ligand binding and activation FGFR1c ligand binding and activation FGFR1c and Klotho ligand binding and activation NCAM signaling for neurite out-growth Signal transduction by L1 Phospholipase C-mediated cascade: FGFR1 Downstream signaling of activated FGFR1 SHC-mediated cascade:FGFR1 PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling Negative regulation of FGFR1 signaling Signaling by FGFR1 in disease Signaling by plasma membrane FGFR1 fusions Epithelial-Mesenchymal Transition (EMT) during gastrulation Formation of paraxial mesoderm Activation of NF-kappaB in B cells RIP-mediated NFkB activation via ZBP1 Downstream TCR signaling NF-kB is activated and signals survival FCERI mediated NF-kB activation TAK1-dependent IKK and NF-kappa-B activation SUMOylation of immune response proteins IkBA variant leads to EDA-ID CLEC7A (Dectin-1) signaling Ub-specific processing proteases Interleukin-1 signaling TRAF6 mediated NF-kB activation SARS-CoV-1 activates/modulates innate immune responses Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Dengue virus modulates apoptosis NOTCH3 Activation and Transmission of Signal to the Nucleus Negative regulation of NOTCH4 signaling PPARA activates gene expression Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Regulation of PTEN gene transcription MECP2 regulates transcription factors MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR ERBB2 Regulates Cell Motility ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate NADPH regeneration Neutrophil degranulation Peroxisomal protein import NFE2L2 regulating TCA cycle genes alectinib sensitve ALK mutants ceritinib-resistant ALK mutants ceritinib-resistant ALK mutants don't bind ceritinib ALK mutants bind type I TKIs

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 32
2Fase 29
1Fase 15
·Pré-clínico4
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Glioblastoma

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

18 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT05917145 · ATM-Inhibitor WSD0628 in Combination With Radiation Therapy …Recrutando
PHASE1
NCT06069726 · A Multicenter Trial to Identify Optimal Atezolizumab Biomark…Recrutando
PHASE2
NCT05969860 · At-Home Cancer Directed Therapy Versus in Clinic for the Tre…Recrutando
PHASE2
NCT07538128 · Evaluating Safety, Tolerability, and Preliminary Efficacy of…Recrutando
EARLY_PHASE1
NCT05698524 · A Study of Temodar With Abexinostat (PCI-24781) for Patients…Recrutando
PHASE1
NCT06466031 · Application of FET-PET in Fusion With MRI in the Treatment o…Recrutando
NA
NCT07100730 · Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Al…Recrutando
PHASE3
NCT07042620 · A Study to Test a New Fluid to Improve the Quality of Images…Recrutando
NA
NCT00083512 · Collection of Blood and Urine Samples in Patients Receiving …Recrutando
NCT06607692 · Study in Children and Adolescents of 177Lu-DOTATATE (Lutathe…Recrutando
PHASE1, PHASE2
NCT06512311 · Personalized Targeted Glioblastoma Therapies by ex Vivo Drug…Recrutando
NA
NCT07326566 · Study of Silevertinib With Temozolomide for the Treatment of…Recrutando
PHASE2
NCT06805305 · DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly …Recrutando
PHASE2
NCT07185880 · A Phase 1/2 Study of the Safety and Tolerability of MT-125 i…Recrutando
PHASE1, PHASE2
NCT06810544 · Safety and Tolerability of TNG456 Alone and in Combination W…Recrutando
PHASE1, PHASE2
NCT06419946 · Lomustine in Addition to Standard of Care in Patients With M…Recrutando
PHASE3
NCT02800486 · Super Selective Intra-arterial Repeated Infusion of Cetuxima…Recrutando
PHASE2
NCT03911388 · HSV G207 in Children With Recurrent or Refractory Cerebellar…Recrutando
PHASE1

Outros ensaios clínicos

2.197 ensaios clínicos encontrados, 32 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
39.444 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 39.444

#1

RFC4 drives temozolomide resistance in glioblastoma by activating STK38-BECN1-dependent autophagy.

Nature communications2026 Mar 23

Este estudo revela que o glioblastoma (GBM) desenvolve resistência à temozolomida (TMZ), sua principal quimioterapia, através da proteína RFC4. A RFC4 ativa um processo de "autofagia" nas células tumorais, tornando-as resistentes ao tratamento ao interagir com a enzima STK38 e a proteína BECN1. A identificação dessa via (RFC4-STK38-BECN1) é crucial, pois oferece uma nova oportunidade para desenvolver terapias mais precisas e superar a resistência em pacientes com GBM.

🇧🇷 traduzido
#2

Deciphering the STAT3-PXN positive feedback loop in GBM, IDH-wildtype: transcriptional regulation and inhibition of YB-1 ubiquitination.

Cell death discovery2026 Mar 23

Em Glioblastoma (GBM) IDH-wildtype, um tipo agressivo de câncer cerebral, o estudo identificou que a elevação do gene PXN está associada a um pior prognóstico e maior malignidade. Mecanicamente, PXN forma um ciclo de autoalimentação com STAT3 e estabiliza a proteína YB-1, ambos processos que contribuem para a agressividade da doença. Compreender esses mecanismos oferece novas direções para o desenvolvimento de tratamentos mais eficazes, buscando atingir esses alvos moleculares.

🇧🇷 traduzido
#3

AATF supports proliferation of glioblastoma cells by sustaining mitochondrial respiration through an NRF-1-dependent mechanism.

Cell death &amp; disease2026 Mar 24

Este estudo revela que o glioblastoma (GBM), um tumor cerebral agressivo, depende criticamente da respiração mitocondrial para sua proliferação, e a proteína AATF, cuja expressão se correlaciona com o prognóstico do paciente, é essencial para essa dependência. A AATF interage com o NRF-1 para sustentar a transcrição de genes da fosforilação oxidativa (OXPHOS), e sua inibição leva à interrupção do crescimento e à redução da formação de tumores. Para pacientes e médicos, essas descobertas posicionam a AATF como um promissor alvo terapêutico para futuras intervenções, oferecendo uma nova estratégia para combater o avanço do glioblastoma.

🇧🇷 traduzido
#4

HNRNPH1 drives glioblastoma progression by regulating the splicing of cell cycle genes.

Cell death &amp; disease2026 Mar 24

Este estudo identificou a proteína HNRNPH1 como um fator crucial para a progressão do Glioblastoma (GBM), sendo super expressa nas células tumorais e essencial para sua divisão e crescimento. Ao silenciar HNRNPH1, observou-se a interrupção do ciclo celular, redução da proliferação e morte das células tumorais, além de inibição do crescimento do tumor e aumento da sobrevida em modelos pré-clínicos. Isso sugere que a HNRNPH1 é um alvo terapêutico promissor, com potencial para o desenvolvimento de novas estratégias de tratamento para pacientes com GBM.

🇧🇷 traduzido
#5

CD47 stabilizes ROBO2 to regulate glioblastoma progression by preventing ITCH-mediated ubiquitination.

Proceedings of the National Academy of Sciences of the United States of America2026 Mar 31

Este estudo revela que a proteína CD47, frequentemente elevada nas áreas invasivas do glioblastoma, está associada a pior sobrevida dos pacientes. Ela impulsiona a progressão do tumor (crescimento e disseminação) de forma intrínseca, independentemente da resposta imune, ao estabilizar a proteína ROBO2, que é crucial para a malignidade. Portanto, o bloqueio da via CD47-ROBO2 representa um promissor novo alvo terapêutico para o tratamento do glioblastoma.

🇧🇷 traduzido

Publicações recentes

Ver todas no PubMed

📚 EuropePMC39.004 artigos no totalmostrando 197

2026

Dual Regulation of Post-Translational Modification of Proteins: Bottlenecks and Breakthroughs in NK Cell Therapy for Glioblastoma.

International journal of general medicine
2026

PAK4 functions as an immune suppressor by reprogramming the phosphatidylcholine metabolism of CD8 + T cells within the glioblastoma tumor microenvironment.

Oncogene
2026

RFC4 drives temozolomide resistance in glioblastoma by activating STK38-BECN1-dependent autophagy.

Nature communications
2026

Deciphering the STAT3-PXN positive feedback loop in GBM, IDH-wildtype: transcriptional regulation and inhibition of YB-1 ubiquitination.

Cell death discovery
2026

AATF supports proliferation of glioblastoma cells by sustaining mitochondrial respiration through an NRF-1-dependent mechanism.

Cell death &amp; disease
2026

HNRNPH1 drives glioblastoma progression by regulating the splicing of cell cycle genes.

Cell death &amp; disease
2026

PRDM players in Central Nervous System Cancers: state of the art and future perspectives.

Critical reviews in oncology/hematology
2026

Recent progress and future directions to advance glioblastoma research: A consensus perspective from the 2024 Christopher Davidson Forum.

Neuro-oncology
2026

Molecularly distinct collision tumor consisting of meningothelial meningioma and glioblastoma, IDH-wildtype: illustrative case.

Journal of neurosurgery. Case lessons
2026

CD47 stabilizes ROBO2 to regulate glioblastoma progression by preventing ITCH-mediated ubiquitination.

Proceedings of the National Academy of Sciences of the United States of America
2026

Exercise-associated microRNA programs as candidate modulators and biomarkers in glioblastoma: a narrative review.

Discover oncology
2026

Biomimetic Nanoplatform for Targeted Glioblastoma Therapy via Concurrently Triggering GPX4/DHODH Mediated Ferroptosis.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2026

Integrative Multi-Omics and Single-Cell Profiling Identify Chitinase Domain Containing Protein 1 (CHID1) as a Prognostic Biomarker in Glioblastoma.

Journal of Cancer
2026

Temporalis Muscle Thickness as a Prognostic Factor for 30-Day, 90-Day, and Overall Mortality in Newly Diagnosed Glioblastoma.

Cureus
2026

Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies.

Journal of immunotherapy and precision oncology
2026

Increased expression of SMAD5-AS1 in glioma is associated with patient prognosis and immunity.

International journal of clinical and experimental pathology
2026

Aptamer-functionalized exosomes combined with doxorubicin suppress GBM progression and enhance chemoradiosensitivity by promoting pyroptosis.

Materials today. Bio
2026

Longitudinal, label-free, high-resolution imaging of glioblastoma spheroid response to therapy: a translational tool for preclinical evaluation of chemotherapy, radiation, and immunotherapy.

Optica
2026

MEG3 in glioma stem cells promotes glioblastoma angiogenesis through FUBP3-mediated VGF expression.

Clinical and experimental medicine
2026

Plant-derived nanocarriers & nanostructures for barrier-defined translation: a comprehensive review of mechanisms, targets, and translation.

Journal of nanobiotechnology
2026

Histogram Analysis of Ultrasound Localization Microscopy for Predicting Isocitrate Dehydrogenase Status in Rat Glioblastoma.

Ultrasound in medicine &amp; biology
2026

Antitumorigenic activity of Rubus sp. fruit extract in C6 rat and U87 human glioma cell lines.

Nutrition (Burbank, Los Angeles County, Calif.)
2026

Recent Development of the Probes for Fluorescence Spectroscopy, Mass Spectrometry and Electron Microscopy in Cancer Diagnosis.

Protein and peptide letters
2026

TRIM44 as a Multifunctional Regulator in Cancer and Non-Cancer Diseases: From Oncogenic Driver to Immune and Stress Response Modulator.

Protein and peptide letters
2026

Nanotechnology-Based Strategies for Glioblastoma: Diagnostic and Therapeutic Advances.

Current neuropharmacology
2026

Glutamate Drives Glioblastoma Invasion in Three-Dimensional Hyaluronic Acid Hydrogels.

Tissue engineering. Part A
2026

Development of Glioblastoma Multiforme in Patients With Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma: A Case Series.

Cancer reports (Hoboken, N.J.)
2026

Macrophage membrane-camouflaged nanoparticles for synergistic gene-phototherapy in glioblastoma.

Brain research bulletin
2026

Construction of ammonia death-related lncRNA prognostic signature model and immunomodulatory effect in glioblastoma multiforme.

Brain research
2026

mRNA-based cancer vaccines: A new frontier in personalized immunotherapy.

Biochimica et biophysica acta. Reviews on cancer
2026

The brain imaging feature-related gene NRP2 drives the malignant progression of glioblastoma through the FAK pathway: a Mendelian randomization study.

Translational oncology
2026

Finely-tuned regulator of DNA repair: FBXW7-185aa may modulate glioblastoma radiosensitization and the tumor immune microenvironment.

Translational oncology
2026

UCHL1 promotes temozolomide resistance in glioblastoma by inhibiting the ubiquitination-mediated degradation of keratin 8.

Translational oncology
2026

EZH2 inhibition in resistant glioblastoma stem cells counteracts oxidative stress protection and triggers ferroptosis.

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
2026

Targeting ULK1 and USP20 to modulate autophagy and chemosensitivity in cancer cell lines.

Biomedical reports
2026

Combined Patch-clamp Electrophysiology and Single-Cell Genomic Analysis Reveal Spiking Tumor Cells at the Neocortical Glioblastoma Interface in Humans.

Neuro-oncology
2026

CALLY index provides improved prognostic stratification compared with other inflammation-based scores in glioblastoma treated with the stupp protocol.

BMC cancer
2026

Reprogramming the immune orchestra for glioblastoma: oncolytic viruses and the B-cell connection.

Cellular &amp; molecular immunology
2026

Exploring the dual role of extracellular vesicles in coagulation and immune modulation in glioblastoma.

Scientific reports
2026

ETV1 Promotes Glioma Progression via miR-3175/STEAP2 Axis.

BioFactors (Oxford, England)
2026

Metabolic Imaging and Molecular Signatures Reveal Metabolic Phenotypes in Recurrent Glioblastoma.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
2026

Unraveling the role of boron microdistribution in BNCT dosimetry of glioblastoma multiforme: combined theoretical and experimental insights.

Physics in medicine and biology
2026

Decoding the biology of the blood-brain tumor barrier in brain cancer.

Molecular cancer research : MCR
2026

RAGE Inhibition Reduces Surgery-Induced Cerebral Edema After Glioma Resection.

Neurosurgery
2026

Discovery, Optimization, and Biological Evaluation of 2-Cyano-2-(9H-xanthen-9-ylidene)acetamide Derivatives as ZNF207 Inhibitors for Anti-Glioma Therapy.

Journal of medicinal chemistry
2026

The TNFR superfamily member Fn14 impacts immunity and survival in experimental gliomas and response to immune checkpoint inhibitor therapy in glioblastoma patients.

Neuro-oncology advances
2026

Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme.

Communications medicine
2026

NANP targeting radiosensitizes glioblastoma through TNFR1 sialylation-driven mesenchymal shift.

Nature communications
2026

Celcomen: spatial causal disentanglement for single-cell and tissue perturbation modeling.

Nature communications
2026

Clinical and molecular features of primary gliosarcoma with digital spatial whole-transcriptome analysis of glial and mesenchymal components.

Brain pathology (Zurich, Switzerland)
2026

Conditional Survival Estimates for Malignant Glioma Patients: Secondary Analysis of RTOG 9006.

American journal of clinical oncology
2026

Integrative computational pipeline for the in silico prioritization of potential KIF11-targeting drug candidates in glioblastoma.

Journal of molecular graphics &amp; modelling
2026

A genetically optimized physics-informed neural network for multiphysics modeling of magnetic hyperthermia in brain cancer.

Computers in biology and medicine
2026

Development and characterisation of a radiobiology proton beamline using radiochromic film dosimetry.

Physics in medicine and biology
2026

Impact of corticosteroid administration on glioblastoma progression before and after adjuvant treatments: recent updates on contradictory findings and mechanistic interactions.

Frontiers in oncology
2026

Antiepileptic drugs in glioblastoma survival: dichotomic or treatment and mechanism of action-dependent variable?

Neuro-oncology advances
2026

Detecting Extrachromosomal DNA from Routine Histopathology.

bioRxiv : the preprint server for biology
2026

Intrinsically disordered SERBP1 regulates translation through topology-driven G-quadruplex recognition.

bioRxiv : the preprint server for biology
2026

Aucan targets CDK2 to suppress glioblastoma progression by inhibiting PI3K/AKT pathway-mediated proliferation and inducing apoptosis.

Biochemical pharmacology
2026

Glioma-induced DNMT3A reduction in microglia promotes an anti-tumoral phenotype.

Cell death and differentiation
2026

A blueprint for local and distal invasion programs in glioblastoma.

Nature communications
2026

Glutamate decarboxylase 1 (GAD1) suppresses the progression of glioblastoma through GSK3β/β-catenin pathway.

Cell death discovery
2026

Synergistic Effects of Curcumin and Temozolomide in Overcoming Glioblastoma Drug Resistance through Regulation of O6-Methylguanine-DNA Methyltransferase, Mismatch Repair, and Poly(Adenosine Diphosphate Ribose) Polymerase 1.

Drug research
2026

Two translocation mechanisms drive neural stem cell dissemination into the human fetal cortex.

Neuron
2026

Microglial fructose metabolism is essential for glioblastoma growth.

Proceedings of the National Academy of Sciences of the United States of America
2026

Synthetic SIGLEC9-based chimeric switch receptor augments the efficacy of CAR macrophages against glioblastoma.

Proceedings of the National Academy of Sciences of the United States of America
2026

PD-L1 Expression in Gliomas: A Potential Immunotherapeutic Target in High-grade Tumours.

Prague medical report
2026

Hybrids of harmine and quinoline-based antimalarials show a strong antiproliferative effect on glioblastoma cells and reverse ATP-binding cassette transporter-mediated drug resistance.

Pharmacological reports : PR
2026

Survival and function in elderly patients with GBM: the role of surgical resection with contemporary multimodal therapy.

Journal of neuro-oncology
2026

Immune checkpoint inhibitors in combination with standard treatment versus standard treatment alone for newly diagnosed glioblastoma: a systematic review and meta-analysis.

Neurosurgical review
2026

Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models.

The Journal of clinical investigation
2026

Peroxidasin promotes malignant progression by enhancing glycolytic metabolism in glioblastoma through the regulation of LDHA.

Neurological research
2026

GlioMODA: Robust glioma segmentation in clinical routine.

Neuro-oncology advances
2026

Concurrent Ferroptosis and Apoptosis in Resveratrol-Treated Glioblastoma Cells: Relevance With NRF2 Downregulation and Oxidative Stress.

Cell biology international
2026

Radiomics-based differentiation between glioblastoma and primary central nervous system lymphoma: CT vs MRI.

Cancer imaging : the official publication of the International Cancer Imaging Society
2026

tLyP-1 peptide-modified MnO₂ co-delivering si-SLC16A1 and temozolomide synergistically suppresses glioblastoma via hypoxia modulation and metabolic stress.

Journal of nanobiotechnology
2026

Pneumocystis jirovecii pneumonia in a chemotherapy-induced immunocompromised patient with glioblastoma multiforme.

BMJ case reports
2026

Immunotherapy Failure in Glioblastoma: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Critical reviews in oncology/hematology
2026

Syntaphilin inhibits glioma invasion via modulating mitochondria redistribution and shapes the immune microenvironment: A potential prognostic biomarker.

Gene
2026

Preclinical validation of tetrahydroquinoline derivatives as EGFR inhibitor inducing glioblastoma cell death.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
2026

Bacoside-A enhances temozolomide-induced cytotoxicity in U87MG glioblastoma cells via ROS-mediated apoptosis and EGFR/MAPK inhibition.

Neuropharmacology
2026

Multi-omics analysis identifies CCNB1 as a cell cycle factor driving glioblastoma progression and its inhibition by resveratrol.

PloS one
2026

Stereotactic Intracranial Implantation of Glioblastoma Patient-derived Xenograft Cell Lines in Mice.

Journal of visualized experiments : JoVE
2026

Identification of new prognostic molecular markers in glioblastoma: a single-center retrospective study.

The oncologist
2026

Integrative multi-omics analysis reveals an 11-gene malignant-myeloid interaction signature and identifies TPST1 as a potential regulator of immunosuppressive microenvironment in glioma.

Discover oncology
2026

MicroRNAs as diagnostic prognostic and therapeutic biomarkers in glioblastoma.

Discover oncology
2026

GPR40 Attenuates Glioma TMZ-Resistance Through Ferroptosis Inhibition.

Neurochemical research
2026

Framework for statistical parametric mapping of the interactions between glioblastoma location, treatment, prognostic variables, and survival using a phase III trial.

Clinical cancer research : an official journal of the American Association for Cancer Research
2026

The Size of Glioblastoma Spheroids Influences Patterns of Invasion and Temozolomide Efficacy.

Tissue engineering. Part C, Methods
2026

Mismatch repair deficiency reshapes glioblastoma through immune suppression rather than hypermutation.

The Journal of clinical investigation
2026

Enhanced Delivery of Aurora Kinase A Inhibitor Alisertib via Tumor-Targeting Immunoliposome Nanocomplex for Improved Treatment of Cancers Including Atypical Teratoid/Rhabdoid Tumor.

International journal of nanomedicine
2026

Closing the loop on glioblastoma: A roadmap toward developing bioelectronics for continuous monitoring of tumor state.

APL bioengineering
2026

Clinical and genetic determinants of glioblastoma survival: a retrospective study.

Frontiers in molecular neuroscience
2026

Adoptive transfer of ILC2s reveals tumor homing in glioblastoma: a proof-of-concept study.

Frontiers in oncology
2026

Volumetric MRI-based response assessment and prognostic value in newly diagnosed glioblastoma: RANO 2.0 versus mRANO versus RANO.

Neuro-oncology advances
2026

Active immunization strategies in glioblastoma - clinical outcomes and effect modifiers for dendritic vaccines and adoptive cell therapies: a systematic review.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2026

Harnessing γδ T cells for B7-H3-targeting CAR therapy to enhance anti-tumor therapy in glioblastoma.

Journal of translational medicine
2026

M2-like GAMs secreting CSTA drive glioblastoma progression via the ITGB4-TGFB1 feedback axis.

Journal of translational medicine
2026

Disrupting Akt-Wnt/β-catenin signaling suppresses glioblastoma stem cell growth and tumor progression in immunocompetent mice.

Journal of neuro-oncology
2026

Constraints, cumulative doses and toxicity outcomes in glioma reirradiation: a systematic review and radiobiological comparison from the Reirradiation Collaborative Group (ReCog).

International journal of radiation oncology, biology, physics
2026

Olfactomedin 1 acts as a tumor suppressor in glioblastoma: integrated analysis and mechanistic prediction.

Neuroscience
2026

Ferritin in motion: How systemic iron balance and tumor trafficking shape glioblastoma.

Biochimica et biophysica acta. Reviews on cancer
2026

Patterns of failure following stereotactic radiosurgery salvage for recurrent high-grade glioma.

Journal of neuro-oncology
2026

BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.

European journal of cancer (Oxford, England : 1990)
2026

Combining Temozolomide with a Selective CK2 Inhibitor Results in Anti-Tumour Effects in Glioblastoma Cell Lines.

Molecules (Basel, Switzerland)
2026

Synthesis and Anticancer Evaluation of PCNA Inhibitor AOH1996 Analogs in Cancer Cell Cultures.

Molecules (Basel, Switzerland)
2026

Heat up and Destroy: Immunotherapy of "Cold" Tumors Using the Example of Glioblastoma.

International journal of molecular sciences
2026

TXRF Spectrometry for Investigating CaF2:Nd3+,Y3+ Nanoparticle Diffusion in Tumoral Cancer 3D Spheroids.

International journal of molecular sciences
2026

AP-2 Transcription Factors as Regulators of Ferroptosis: A Family-Wide Profiling in Diverse Cancer Contexts.

International journal of molecular sciences
2026

Advancements in Drug Delivery Systems in Glioblastoma Therapy.

International journal of molecular sciences
2026

Targeting BRD4-A Promising Therapeutic Option for Glioblastoma?

International journal of molecular sciences
2026

Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.

International journal of molecular sciences
2026

The Natural Triterpenoid Alisol B Overcomes Temozolomide Resistance in Glioblastoma Through Multi-Target Mechanisms: Coordinated Epigenetic, Metabolic, and Cell-Cycle Reprogramming.

International journal of molecular sciences
2026

Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens.

Diagnostics (Basel, Switzerland)
2026

Exosome Engineering for Blocking Gut Dysbiosis and Inducing Cell Death Mechanisms in Glioblastoma Multiforme.

Cells
2026

Neuro-Oncological Perspectives on Cancer Stem Cell Biology in Glioblastoma: Implications for Resection, Recurrence, Targeted Therapy, and Other CNS Tumors.

Cells
2026

MGMT Promoter and Enhancer Methylation in Melanoma Brain Metastases and Glioblastoma: Shared and Distinct Features.

Cells
2026

Translating Molecular Insights into Effective Targeting of Glioblastoma Stem Cells.

Cancers
2026

Resveratrol and AG490 Overcome Glioblastoma Cells' Resistance to Monotherapy by Inhibiting JAK2/STAT3 Signalling Pathway.

Cancers
2026

Targeted radio-thermo dual sensitizer magnetic gold core-shells nanoparticles enhance radioresistant glioblastoma via promoting apoptosis and ROS generation.

Cancer cell international
2026

Myeloid-derived immunosuppression of chimeric antigen receptor T cells in the neuronal microenvironment of glioblastoma.

BMC medicine
2026

Tumor immunogenicity shapes CNS immune niches and CD8⁺ T cell fate in glioblastoma.

Journal of neuroinflammation
2026

Exploiting Metabolic Dependencies for Therapeutic Targeting of Brain Cancers.

Cancer letters
2026

Estimating time-dependent cell survival in particle beam thermoradiotherapy with the dynamic temperature-dependent stochastic microdosimetric kinetic model.

Physics in medicine and biology
2026

Speech mapping in awake high-grade glioma resection: subcortical tract proximity as a predictor of language outcomes.

Journal of neurosurgery
2026

Effect of anticancer activity of aripiprazole main metabolite OPC-14857 on malignant glioblastoma.

PloS one
2026

FET PET Does Not Improve Outcomes Compared with MRI for Re-Irradiation of Recurrent Glioblastoma: GLIAA/NOA-10 ARO2013-01 Trial.

Radiology. Imaging cancer
2026

[Retracted] Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine‑γ‑lyase function.

Oncology reports
2026

EGFRvIII expression in head and neck squamous cell carcinoma: clinical significance and sources of frequency variation across studies.

Frontiers in oncology
2026

Focused ultrasound for blood-brain barrier opening in brain tumor patients: Technical nuances.

Neuro-oncology advances
2026

Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial.

Cancer communications (London, England)
2026

Assessment of pTERT Subtypes of Glioblastoma by Quantitative FLAIR Analysis Based on Fusing MRI Images.

Brain and behavior
2026

The lysine methyltransferase KMT5a and p53 regulate the expression of the key autophagy adaptor p62/SQSTM1 in glioblastoma.

Cell communication and signaling : CCS
2026

Endogenous immune recruitment in glioblastoma CAR T therapy: cytokine, myeloid, and chemokine circuitry.

Journal of neuro-oncology
2026

Metabolic dependencies and neural progenitor dysregulation: driving forces in paediatric high-grade glioma development.

Cancer metastasis reviews
2026

Matrix stress relaxation promotes glioblastoma cell migration in a ligand-specific manner.

Scientific reports
2026

A lysosomal requiem for glioblastoma cells.

Trends in cancer
2026

Eligibility assessment for yttrium-90 radioembolisation in patients with recurrent glioblastoma: A single-centre cohort study based on the FRONTIER clinical trial criteria (NCT05303467).

Radiologia
2026

Synthesis and characterization of new P2X7 receptor antagonists as antitumor agents.

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
2026

Racial Disparities in Glioblastoma: Can We Untangle Biological From Nonbiological Forces?

JCO oncology practice
2026

USP7 facilitates brain tumor survival upon glucose deprivation by regulating phosphofructokinase muscle-type nuclear translocation in mice.

PLoS biology
2026

MGMT downregulation by CRISPR/Cas13 RNA-guided RNA targeting enhances glioma cell sensitivity to TMZ chemotherapy.

Journal of neuro-oncology
2026

Glioma-Immune crosstalk in the tumor microenvironment: mechanistic insights and therapeutic translation.

Medical oncology (Northwood, London, England)
2026

TERT Promoter Methylation in Glioblastoma and its Paradoxical Association with Upregulated Gene Expression.

Neurology India
2026

A novel mucosa-associated lymphoid tissue translocation gene 1-related immune prognostic signature and targeted drug screening for glioblastoma.

Brain circulation
2026

Does coordinated targeting of metabolism and autophagy, modulated by microtubule dynamics, influence therapeutic vulnerability to eribulin in glioblastoma?

Translational cancer research
2026

[Xihuang Pills induce mitochondria-associated ferroptosis to enhance therapeutic efficacy of temozolomide against glioblastoma via Nrf2/HO-1/GPX4 signaling axis].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
2026

Expanding the Inhibitory Potential of the Benzoxaborinine Scaffold against Carbonic Anhydrases: Synthesis, Structural Characterization, and In Vitro Antitumor Activity.

Journal of medicinal chemistry
2026

Rapid and sensitive detection of cancer-derived small extracellular vesicles using Janus particles.

Nature biomedical engineering
2026

Corrigendum to "Nose-to-brain delivery of sorafenib-loaded lipid-based poloxamer-carrageenan nanoemulgel: Formulation and therapeutic investigation in glioblastoma-induced orthotopic rat model" [Int. J. Biol. Macromol. 309 (2025) 142861].

International journal of biological macromolecules
2026

The redox paradox in HGGs: ROS as drivers and destroyers.

Trends in cancer
2026

Iodinated contrast agents decrease the activity of multidrug resistance protein, cell migration, and induce cell death in different tumor cell lines and glioblastoma spheroids.

Biochimica et biophysica acta. General subjects
2026

A Supportive Group Intervention for Caregivers to Patients Diagnosed With Glioblastoma: Protocol for the SUGRI Study.

JMIR research protocols
2026

Cytoskeletal remodeling promotes tunneling nanotube formation and drives cardiac resident cell mitochondrial transfer in sepsis.

Science advances
2026

CC8, a heterodimeric disintegrin from Cerastes cerastes snake venom, triggers apoptosis and restrains the dissemination of human glioblastoma cells.

Pharmacological reports : PR
2026

Investigation of the impact of D, L-methadone on ALA-PDT in multiple glioblastoma cell lines.

Photochemical &amp; photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
2026

Socioeconomic disparities in IDH-wildtype glioblastoma survival: interactions between age and household income in a SEER cohort.

Journal of neuro-oncology
2026

A Biomimetic Nanoplatform for Near-Infrared-Assisted Heat-Mediated Synergistic Therapy for Glioblastoma.

ACS applied bio materials
2026

The promise and potential of porphyrin metabolite activation using sonodynamic therapy for the treatment of glioblastoma.

Journal of neuro-oncology
2026

Exosomal Lnc-DLK1-35 reprograms microglia into a pro-tumorigenic phenotype via a non-canonical cytokine signature to promote glioblastoma progression and chemoresistance.

Folia histochemica et cytobiologica
2026

Role of human RNase 7 in neuronal and glial cell models: moving towards an unexpected new functional link.

The FEBS journal
2026

Gliosarcoma: A Reappraisal of Neuroradiological, Surgical, Morphological, and Radiotherapeutic Characteristics of a Cohort From South Italy Single-Center.

Analytical cellular pathology (Amsterdam)
2026

Identification of the Antioxidant Enzyme B166 as a Novel Biomarker for Patients With Glioblastoma Multiforme.

Analytical cellular pathology (Amsterdam)
2026

Spatial Transcriptomics Meets Histochemistry: Insights from Glioblastoma as a Model System.

Acta histochemica et cytochemica
2026

Targeting MGAT4A-Mediated N-Glycosylation as a Therapeutic Strategy to Inhibit Glioblastoma Stem Cell Invasion.

Exploration (Beijing, China)
2026

The Shifting Prognostic Value of Performance Status in Aging Glioblastoma Patients: A Retrospective Cohort Study.

Clinical interventions in aging
2026

Brain-targeting nanoplatform repurposing silymarin for enhanced GBM immunotherapy via synergistic mitochondrial suppression.

Materials today. Bio
2026

Recurrent Glioblastoma and the Tumor Immune Landscape: Emerging Immunotherapeutic Strategies.

ImmunoTargets and therapy
2026

miR-181d coordinates homologous recombination and anti-tumor immune responses in glioblastoma.

iScience
2026

Endoscopic Transorbital Approach for Select Recurrent and Newly Diagnosed Anteromedial Temporal Lobe Gliomas.

Journal of neurological surgery. Part B, Skull base
2026

A Brain-Targeting Curcumin Analog Inhibits Glioblastoma Progression Through THBS1/TGF-β1/PI3K-AKT Axis Modulation: Evidence From Experimental and Bioinformatic Analyses.

Journal of cellular and molecular medicine
2026

Evolving landscape of glioblastoma research : A 75-year bibliometric study on survival, treatment and gender in authorship.

Wiener klinische Wochenschrift
2026

Pan-cancer analysis of NTRK2 (TRKB) and the anticancer effect of its inhibitor Lucitanib in glioma.

Computational biology and chemistry
2026

Glioblastoma survival in rural America: a 10-year experience from a quaternary care center.

Journal of neuro-oncology
2026

First-in-Class Small Molecule Inhibitor of Oncogene AVIL in Glioblastoma.

DNA and cell biology
2026

Porous organosilica nanoparticles enable UV blocking and two-photon fluorescence imaging.

Journal of materials chemistry. B
2026

Radiomics in glioblastoma recurrence: advances in prediction, localization, and differentiation from treatment-related effects.

Journal of translational medicine
2026

Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma.

Nature communications
2026

DLD, upregulated by YY1, fuels glioblastoma multiforme progression via EphA2 phosphorylation to activate PI3K/AKT/mTOR.

QJM : monthly journal of the Association of Physicians
2026

Dual role of LY96 in shaping the mesenchymal glioblastoma ecosystem through stem cell maintenance and macrophage MES-like reprogramming.

Cancer letters
2026

Association of CDKN2A/B and MTAP deletions in adult-type diffuse gliomas.

Journal of neuropathology and experimental neurology
2026

Investigation of the impact of resveratrol on sublethal-dose ALA-PDT in glioblastoma cells.

Photochemical &amp; photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
2026

Formyl Peptide Receptor-2-Suppressed Autophagy Promotes the Migration and Invasion of Human Glioblastoma Cells Through PI3K/Akt Signaling.

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
2026

Neurosurgical leadership in neuro-oncology clinical trials: A nationwide study.

Neurosurgical review
2026

Survival and prediction of distant recurrence in glioblastoma.

Neurologia i neurochirurgia polska
2026

Progress in the research and development of oncolytic virus therapies.

Frontiers in pharmacology
2026

[64Cu]Cu-Labeled αCD11b Diabody as a Novel PET Tracer for the Detection of Immunosuppression in Glioblastoma.

ACS omega
2026

High-grade gliomas and Lynch syndrome: A retrospective descriptive study with a literature review.

Neuro-oncology practice
2026

Health-related quality of life outcomes of surgery for diffuse glioma: A systematic review and pooled analysis.

Neuro-oncology practice
2026

Gliosarcoma of the right cerebellar hemisphere and parahippocampal region: A case report and literature review.

Oncology letters
2026

IGF2BP3-GP130-STAT3-WTAP loop promotes the malignant progression in glioblastoma.

Cellular signalling
2026

DENND2D serves as a novel prognostic biomarker with paradoxical protumorigenic effects in glioma.

Discover oncology
2026

Comprehensive analysis of the potential role of Ferroptosis-related genes in glioblastoma multiforme.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Electrochemically optimized multi-component polyacrylonitrile nanofiber scaffolds as a platform for three-dimensional glioblastoma cell culture.

Scientific reports
2026

L1CAM Promotes the Infiltrative Properties of Patient-Derived Glioblastoma Cells.

Cancer science
2026

A near-infrared fluorescent probe for HClO detection and image-guided surgery in glioblastoma.

Bioorganic chemistry
2026

Machine learning model on multi-omics data enables risk stratification and identifies molecular heterogeneity and therapeutic targets in glioblastoma.

Molecular cancer
Ver todos os 39.004 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Glioblastoma.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Glioblastoma

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. RFC4 drives temozolomide resistance in glioblastoma by activating STK38-BECN1-dependent autophagy.
    Nature communications· 2026· PMID 41872171mais citado
  2. Deciphering the STAT3-PXN positive feedback loop in GBM, IDH-wildtype: transcriptional regulation and inhibition of YB-1 ubiquitination.
    Cell death discovery· 2026· PMID 41872167mais citado
  3. AATF supports proliferation of glioblastoma cells by sustaining mitochondrial respiration through an NRF-1-dependent mechanism.
    Cell death &amp; disease· 2026· PMID 41872157mais citado
  4. HNRNPH1 drives glioblastoma progression by regulating the splicing of cell cycle genes.
    Cell death &amp; disease· 2026· PMID 41872153mais citado
  5. CD47 stabilizes ROBO2 to regulate glioblastoma progression by preventing ITCH-mediated ubiquitination.
    Proceedings of the National Academy of Sciences of the United States of America· 2026· PMID 41871254mais citado
  6. Lactate-induced lactylation enhances BMAL1 transcription and nuclear translocation, promoting bevacizumab resistance in glioblastoma through VEGFA.
    Clin Cancer Res· 2026· PMID 41995718recente
  7. Design, Synthesis and Evaluation of Anticancer Potential of Novel Pyrrolopyrazines Against Glioblastoma: Mechanistic Details and In Vivo Safety Analysis.
    Arch Pharm (Weinheim)· 2026· PMID 41994945recente
  8. EMILIN-1 in the tumor microenvironment: insights from CNS tumors and beyond.
    Front Oncol· 2026· PMID 41994657recente
  9. Plasminogen activator inhibitor-1 as an oncologic target: biology, therapeutic inhibitors, and clinical translation.
    Front Oncol· 2026· PMID 41994645recente
  10. The autophagy switch: A critical determinant of arsenic-induced carcinogenesis and cancer therapy.
    Toxicol Rep· 2026· PMID 41994101recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:360(Orphanet)
  2. MONDO:0018177(MONDO)
  3. GARD:2491(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Glioblastoma
Compêndio · Raras BR

Glioblastoma

ORPHA:360 · MONDO:0018177
Prevalência
1-9 / 100 000
Herança
Multigenic/multifactorial, Not applicable
CID-10
C71.9 · Neoplasia maligna do encéfalo, não especificado
CID-11
Ensaios
32 ativos
Início
All ages
Prevalência
1.0 (Worldwide)
MedGen
UMLS
C1621958
Repurposing
2 candidatos
carmustineDNA alkylating agent|DNA inhibitor
temozolomideDNA alkylating agent
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades